BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Debangshu Samanta, Tina Huang, Rima Shah, Yongkang Yang, Fan Pan, Gregg L. Semenza
Abstract
T cells and natural killer cells to BIRC2-deficient tumors. Most importantly, BIRC2 deficiency dramatically increases the sensitivity of mouse melanoma and breast tumors to anti-CTLA4 and/or anti-PD1 ICB.
Topics & Concepts
Cancer researchImmune checkpointCancer immunotherapyImmune systemImmunotherapyCD8MelanomaCytotoxic T cellImmunologyChemokineCXCL9AntibodyT cellBiologyMedicineChemokine receptorIn vitroBiochemistryCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionImmunotherapy and Immune Responses